Literature DB >> 31709044

Microbiome Modulation in Liver Disease.

Eamonn M M Quigley1.   

Abstract

Entities:  

Year:  2019        PMID： 31709044      PMCID： PMC6832094          DOI： 10.1002/cld.862

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  11 in total

Review 1.  A clinician's guide to microbiome analysis.

Authors:  Marcus J Claesson; Adam G Clooney; Paul W O'Toole
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-09       Impact factor: 46.802

2.  Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Brett R Loman; Diego Hernández-Saavedra; Ruopeng An; R Scott Rector
Journal:  Nutr Rev       Date:  2018-11-01       Impact factor: 7.110

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

4.  Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

Authors:  Radha K Dhiman; Baldev Rana; Swastik Agrawal; Ashish Garg; Madhu Chopra; Kiran K Thumburu; Amit Khattri; Samir Malhotra; Ajay Duseja; Yogesh K Chawla
Journal:  Gastroenterology       Date:  2014-08-27       Impact factor: 22.682

5.  Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.

Authors:  Jasmohan S Bajaj; Zain Kassam; Andrew Fagan; Edith A Gavis; Eric Liu; I Jane Cox; Raffi Kheradman; Douglas Heuman; Jessica Wang; Thomas Gurry; Roger Williams; Masoumeh Sikaroodi; Michael Fuchs; Eric Alm; Binu John; Leroy R Thacker; Antonio Riva; Mark Smith; Simon D Taylor-Robinson; Patrick M Gillevet
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

Review 6.  Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.

Authors:  Huikuan Chu; Yi Duan; Ling Yang; Bernd Schnabl
Journal:  Gut       Date:  2018-08-31       Impact factor: 23.059

7.  The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.

Authors:  Muhammad Y Khan; Albana B Mihali; Muhammad S Rawala; Aysha Aslam; Waqas J Siddiqui
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-06       Impact factor: 2.566

Review 8.  Alcohol, liver disease and the gut microbiota.

Authors:  Jasmohan S Bajaj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-04       Impact factor: 46.802

Review 9.  Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.

Authors:  J S Bajaj
Journal:  Aliment Pharmacol Ther       Date:  2016-01       Impact factor: 8.171

10.  A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.